UK Markets closed

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.9195-0.0005 (-0.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.9200
Open0.9300
Bid0.9001 x 800
Ask0.9258 x 1000
Day's range0.9001 - 0.9400
52-week range0.9000 - 3.0600
Volume70,942
Avg. volume71,814
Market cap34.881M
Beta (5Y monthly)1.33
PE ratio (TTM)N/A
EPS (TTM)-0.2880
Earnings date16 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    AgeX Therapeutics Reports Second Quarter 2021 Financial Results

    ALAMEDA, Calif., August 13, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.

  • Business Wire

    AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

    ALAMEDA, Calif. & PITTSBURGH, July 23, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was in

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.